01—Abstract
Summary
Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.
ResMed Inc. (NYSE: RMD, ASX: RMD) reported results for the fourth quarter and fiscal year ended June 30, 2025, in a press release furnished as Exhibit 99.1.
Fourth-quarter revenue rose 10% to $1,348.0 milliona (up 9% on a constant currency basis), and gross margin improved 230 basis points to 60.8%. GAAP income from operations increased 19% to $454.5 million, and diluted EPS was $2.58, up 30%, while non-GAAP diluted EPS was $2.55, up 23%. Operating cash flow for the quarter was $538.8 million.
For the full fiscal year, revenue increased 10% to $5,146.3 millionb, and GAAP income from operations rose 28% to $1,685.4 million. GAAP diluted EPS was $9.51 and non-GAAP diluted EPS was $9.55. Operating cash flow was $1.75 billion, and cash and cash equivalents closed the year at $1,209.5 million, up from $238.4 million a year earlier.
The company also reported that it paid $78 millionc in dividends and repurchased 419,000 shares for $100 million during the quarter. The board declared a quarterly cash dividend of $0.60 per share, a 13% increase, with a record date of August 14, 2025, payable September 18, 2025, and an ex-dividend date of August 13, 2025. The company also announced its pending acquisition of VirtuOx, an independent diagnostic testing facility for sleep, respiratory, and cardiac conditions.
02—Key points
Key Highlights
- Q4 FY2025 revenue rose 10% to $1,348.0 million, with 9% growth on a constant currency basis.
- Q4 gross margin expanded 230 basis points to 60.8%, driven by procurement, manufacturing, logistics efficiencies and favorable foreign currency movements.
- Full-year FY2025 GAAP income from operations increased 28% to $1,685.4 million; non-GAAP income from operations rose 19% to $1,763.3 million.
- Full-year operating cash flow was $1.75 billion, compared with $1.40 billion in the prior fiscal year.
- Quarterly dividend increased 13% to $0.60 per share, with an ex-dividend date of August 13, 2025.
- Announced the acquisition of VirtuOx, an independent diagnostic testing facility for sleep, respiratory, and cardiac conditions.
- Residential Care Software revenue rose 10% to $167.0 million in Q4 (9% on a constant currency basis).
03—Questions
Frequently Asked Questions
How did ResMed perform in the fourth quarter of fiscal 2025?
Revenue grew 10% to $1,348.0 million (9% constant currency). GAAP income from operations increased 19% to $454.5 million, and GAAP diluted EPS was $2.58 versus $1.98 a year earlier. Non-GAAP diluted EPS rose 23% to $2.55.
What drove the improvement in gross margin?
The company attributed the 230 basis point increase in gross margin to procurement, manufacturing and logistics efficiencies, as well as favorable foreign currency movements. Non-GAAP gross margin rose by the same amount to 61.4%.
What is the dividend and when must investors act to receive it?
The board declared a quarterly cash dividend of $0.60 per share. The ex-dividend date is August 13, 2025, the record date is August 14, 2025, and payment is scheduled for September 18, 2025. CDI holders on the ASX will receive an equivalent amount in Australian currency.
How did ResMed's full-year fiscal 2025 results compare with fiscal 2024?
Revenue rose 10% to $5,146.3 million and GAAP diluted EPS rose 37% to $9.51. Non-GAAP diluted EPS was $9.55 versus $7.72 a year earlier. Full-year operating cash flow was $1.75 billion, and cash and cash equivalents ended the year at $1,209.5 million.
What did ResMed spend on capital returns and acquisitions this quarter?
During the quarter the company paid $78 million in dividends and repurchased 419,000 shares for $100 million. It also announced its acquisition of VirtuOx, a diagnostic testing provider for sleep, respiratory, and cardiac conditions.
04—Continue